Abivax’s stock rose 27% on June 30, 2026, after new clinical data covering 4,128 patient-years showed no increased cancer risk for its ulcerative colitis drug obefazimod. The FDA confirmed the updated dataset will inform its October 2026 PDUFA decision. Abivax holds €192.7 million in cash, with EMA review underway and PMDA submission planned for August 2026. CEO Dr. Hartmut Ehrlich stated the data reinforce confidence in the drug’s long-term safety.
According to www.bloomberg.com, Abivax SA’s share price surged 27% on June 30, 2026, following a clinical trial update that alleviated investor concerns about potential cancer-related safety signals.
Clinical Data Reassures Investors
The French biopharmaceutical company disclosed new findings from its Phase 3 ABATE-UC trial evaluating obefazimod — an oral, first-in-class immunomodulator — in patients with moderate-to-severe ulcerative colitis. The updated safety analysis covered 4,128 patient-years of exposure across all clinical studies, including long-term extension data. No statistically significant increase in malignancy incidence was observed compared to placebo or standard-of-care comparators. The median treatment duration in the pooled dataset was 2.3 years, with some patients followed for up to 5.1 years.
These results directly addressed a key regulatory and market concern raised earlier in 2026, when the U.S. Food and Drug Administration (FDA) requested additional carcinogenicity assessment as part of its review of Abivax’s Biologics License Application. According to the report, the FDA acknowledged receipt of the updated dataset and confirmed it would be incorporated into the ongoing evaluation timeline for the BLA, which remains on track for a decision by the PDUFA date of October 2026.
Market Reaction and Financial Context
Abivax’s shares closed at €14.82 on June 30, 2026 — the highest intraday level since March 2025. Trading volume exceeded 2.4 million shares, more than triple the 30-day average. The jump erased nearly all losses incurred over the prior three months, during which the stock had declined 34% amid heightened scrutiny of obefazimod’s preclinical tumor promotion signals in rodent models.
The company reported cash and cash equivalents of €192.7 million as of March 31, 2026, sufficient to fund operations into Q2 2027 based on current burn rate projections. Abivax has not raised external capital since its €115 million follow-on offering in November 2025.
Regulatory Pathway and Next Steps
Abivax confirmed that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for obefazimod, with a validation decision issued on May 15, 2026. The EMA’s Committee for Medicinal Products for Human Use (CHMP) is scheduled to begin its substantive review in Q3 2026, targeting an opinion by early 2027. In parallel, the company plans to submit supplemental data to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) by August 2026.
“This comprehensive safety update provides robust real-world evidence supporting obefazimod’s favorable benefit-risk profile,” said Dr. Hartmut Ehrlich, Chief Medical Officer of Abivax.
“The absence of elevated cancer risk across extended follow-up strongly reinforces our confidence in obefazimod’s long-term use in chronic inflammatory bowel disease.” — Dr. Hartmut Ehrlich, Chief Medical Officer, Abivax
The company emphasized that no new safety signals emerged in the updated analysis, and the overall adverse event profile remained consistent with prior reports — dominated by mild-to-moderate gastrointestinal events.
Obefazimod targets the AP-1 transcription factor pathway, a mechanism distinct from anti-TNF or integrin inhibitors. Its development program includes two pivotal Phase 3 trials: ABATE-UC (n = 622) and ABA-UC-2 (n = 618), both meeting primary endpoints of clinical remission at week 10.
Source: Bloomberg
Compiled from international media by the SCI.AI editorial team.
